Patents by Inventor Boro Dropulic

Boro Dropulic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to Treat Cancer with Engineered T-Cells
    Publication number: 20250090631
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: December 4, 2024
    Publication date: March 20, 2025
    Inventors: Boro Dropulic, Rimas Orentas, Dina Schneider, Winfried Krueger
  • Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
    Publication number: 20250084166
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 18, 2024
    Publication date: March 13, 2025
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Method to treat cancer with engineered T-cells
    Patent number: 12193995
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 14, 2025
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Boro Dropulic, Rimas J. Orentas, Dina Schneider, Winfried Krueger
  • COMPOSITIONS AND METHODS FOR TREATING HIV/AIDS WITH IMMUNOTHERAPY
    Publication number: 20240368256
    Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
    Type: Application
    Filed: May 20, 2024
    Publication date: November 7, 2024
    Inventors: Kim Anthony Gonda, Dina Schneider, Rimas J. Orentas, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
    Patent number: 12122831
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 22, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20240307448
    Abstract: Self-driving surface antigen-regulated promoter-therapeutic payload constructs containing antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the surface antigen-regulated promoter-therapeutic payload constructs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making self-driving surface antigen-regulated promoter-therapeutic payload constructs in T-cells are also disclosed.
    Type: Application
    Filed: April 2, 2024
    Publication date: September 19, 2024
    Inventors: Dina Schneider, Boro Dropulic, Brian Robert Webster
  • Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
    Publication number: 20240309102
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: June 5, 2024
    Publication date: September 19, 2024
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhong Zhu
  • Compositions and methods for treating cancer with anti-CD123 immunotherapy
    Patent number: 12037403
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: July 16, 2024
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating HIV/AIDS with immunotherapy
    Patent number: 12024554
    Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: July 2, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Kim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
  • Chimeric Antigen Receptors and Methods of Use
    Publication number: 20240150773
    Abstract: Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: January 10, 2024
    Publication date: May 9, 2024
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic
  • Compositions and methods for treating cancer with self-driving chimeric antigen receptors
    Patent number: 11969443
    Abstract: Self-driving surface antigen-regulated promoter-therapeutic payload constructs containing antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the surface antigen-regulated promoter-therapeutic payload constructs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making self-driving surface antigen-regulated promoter-therapeutic payload constructs in T-cells are also disclosed.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: April 30, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Boro Dropulic, Brian Robert Webster
  • Compositions and methods for treating cancer with anti-mesothelin immunotherapy
    Patent number: 11970528
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: April 30, 2024
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD22 Immunotherapy
    Publication number: 20240108706
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Application
    Filed: December 4, 2023
    Publication date: April 4, 2024
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy
    Publication number: 20240067724
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: June 7, 2023
    Publication date: February 29, 2024
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Chimeric antigen receptors and methods of use
    Patent number: 11905515
    Abstract: Chimeric antigen receptors containing tumor necrosis factor receptor superfamily member transmembrane domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: February 20, 2024
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic
  • Compositions and Methods for Treating Cancer with DuoCARs
    Publication number: 20240043497
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 8, 2024
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19/CD20 IMMUNOTHERAPY
    Publication number: 20240034802
    Abstract: Chimeric antigen receptors containing CD19/CD20 or CD20/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: May 4, 2023
    Publication date: February 1, 2024
    Inventors: Rimas J. Orentas, Boro Dropulic, Dina Schneider
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DUOCARS
    Publication number: 20240025962
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: July 6, 2023
    Publication date: January 25, 2024
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD22 immunotherapy
    Patent number: 11878052
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: January 23, 2024
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11802142
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: October 31, 2023
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic